Literature DB >> 32767963

The role of cytoreductive nephrectomy in renal cell carcinoma patients with liver metastasis.

Boda Guo1, Shengjing Liu2, Miao Wang3, Huimin Hou3, Ming Liu1.   

Abstract

It is widely accepted that renal cell carcinoma (RCC) with liver metastasis (LM) carries a dismal prognosis. We aimed to explore the value of cytoreductive nephrectomy among these patients. Patients were extracted from the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2017. The univariate and multivariate Cox proportional hazards models were conducted to select the prognostic predictors of survival. Patients were divided into nephrectomy and non-nephrectomy groups. Propensity score-matching (PSM) analyses were applied to reduce the above factors' differences between the groups. Overall survival (OS) was compared by Kaplan-Meier analyses. Data from 683 patients were extracted from the database. The univariate Cox regression and multivariate Cox regression revealed that factors including age, histologic type, T and N stages, lung metastasis, brain metastasis, and nephrectomy were significant predictors of survival in the patients. After the PSM analyses, we found that nephrectomy prolonged OS. Nephrectomy can prolong OS in eligible RCC patients with LM.

Entities:  

Year:  2021        PMID: 32767963      PMCID: PMC7982060          DOI: 10.17305/bjbms.2020.4896

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  26 in total

1.  Hepatectomy for metastatic renal cell carcinoma.

Authors:  S Fujisaki; T Takayama; K Shimada; J Yamamoto; T Kosuge; S Yamasaki; K Tobisu; Y Kurosu; M Makuuchi
Journal:  Hepatogastroenterology       Date:  1997 May-Jun

2.  Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy.

Authors:  Boris Gershman; Daniel M Moreira; Stephen A Boorjian; Christine M Lohse; John C Cheville; Brian A Costello; Bradley C Leibovich; R Houston Thompson
Journal:  Eur Urol       Date:  2015-06-01       Impact factor: 20.096

3.  Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?

Authors:  Stephen H Culp; Nizar M Tannir; E Jason Abel; Vitaly Margulis; Pheroze Tamboli; Surena F Matin; Christopher G Wood
Journal:  Cancer       Date:  2010-07-15       Impact factor: 6.860

4.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

5.  Combined nephrectomy and major hepatectomy: indications, outcomes, and recommendations.

Authors:  Maksym Yezhelyev; Viraj Master; Vasili Egnatashvili; David A Kooby
Journal:  J Am Coll Surg       Date:  2009-03       Impact factor: 6.113

6.  Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

Authors:  Arnaud Méjean; Alain Ravaud; Simon Thezenas; Sandra Colas; Jean-Baptiste Beauval; Karim Bensalah; Lionnel Geoffrois; Antoine Thiery-Vuillemin; Luc Cormier; Hervé Lang; Laurent Guy; Gwenaelle Gravis; Frederic Rolland; Claude Linassier; Eric Lechevallier; Christian Beisland; Michael Aitchison; Stephane Oudard; Jean-Jacques Patard; Christine Theodore; Christine Chevreau; Brigitte Laguerre; Jacques Hubert; Marine Gross-Goupil; Jean-Christophe Bernhard; Laurence Albiges; Marc-Olivier Timsit; Thierry Lebret; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-06-03       Impact factor: 91.245

Review 7.  Synchronous nephrectomy and right hepatectomy for metastatic chromophobe renal cell carcinoma: report of a case and review of the literature.

Authors:  Fernando Talarico; Pierfrancesco Buli; Domenico Iusco; Antonio Sangiorgi; Elio Jovine
Journal:  Chir Ital       Date:  2007 Mar-Apr

8.  Synchronous Metastasis Rates in T1 Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Results Database-based Study.

Authors:  Angela Pecoraro; Carlotta Palumbo; Sophie Knipper; Francesco A Mistretta; Giuseppe Rosiello; Zhe Tian; Pierre-Antoine St-Hilaire; Shahrokh F Shariat; Fred Saad; Luke Lavallée; Alberto Briganti; Anil Kapoor; Cristian Fiori; Francesco Porpiglia; Pierre I Karakiewicz
Journal:  Eur Urol Focus       Date:  2020-03-10

9.  First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.

Authors:  Andrew W Hahn; Zachary Klaassen; Neeraj Agarwal; Benjamin Haaland; John Esther; Xiang Y Ye; Xuechen Wang; Sumanta K Pal; Christopher J D Wallis
Journal:  Eur Urol Oncol       Date:  2019-10-04

10.  Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: over 10 years of experience.

Authors:  Alexis Gonnet; Laura Salabert; Guilhem Roubaud; Vittorio Catena; Véronique Brouste; Xavier Buy; Marine Gross Goupil; Alain Ravaud; Jean Palussière
Journal:  BMC Cancer       Date:  2019-12-03       Impact factor: 4.430

View more
  2 in total

1.  Identification of Immune-Related Subtypes and Characterization of Tumor Microenvironment Infiltration in Kidney Renal Clear Cell Carcinoma.

Authors:  Huisheng Qin; Tiancheng Wang; Hui Zhang
Journal:  Front Genet       Date:  2022-06-29       Impact factor: 4.772

2.  Patterns of distant metastases in patients with clear cell renal cell carcinoma--A population-based analysis.

Authors:  Jianxin Xue; Wensun Chen; Wenbo Xu; Zicheng Xu; Xiao Li; Feng Qi; Zengjun Wang
Journal:  Cancer Med       Date:  2020-11-28       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.